IPF Research

See below for the latest in research news related to Idiopathic Pulmonary Fibrosis (IPF). This is where the PFF will share relevant news articles, press releases, and study results in the field of IPF.

Galecto Advances Phase 2b Study of GB0139 in Idiopathic Pulmonary Fibrosis; Recruitment Remains on Track Despite COVID-19 Crisis
- by Kelsey Overberg
- May 12, 2020
Full story: Galecto Advances Phase 2b Study of GB0139 in Idiopathic Pulmonary Fibrosis; Recruitment Remains on Track Despite COVID-19 Crisis
I-Mab Announces IND Clearance from FDA for TJM2 to Treat Cytokine Release Syndrome (CRS) Associated with Severe Coronavirus Disease 19 (COVID-19)
- by Kelsey Overberg
- Apr 17, 2020
Full story: I-Mab Announces IND Clearance from FDA for TJM2 to Treat Cytokine Release Syndrome (CRS) Associated with Severe Coronavirus Disease 19 (COVID-19)
FDA GRANTS CALCIMEDICA PERMISSION TO BEGIN DOSING CM4620-IE IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA UNDER A NEWLY OPENED IND
- by Kelsey Overberg
- Apr 17, 2020
Full story: FDA GRANTS CALCIMEDICA PERMISSION TO BEGIN DOSING CM4620-IE IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA UNDER A NEWLY OPENED IND
How a 100-year-old vaccine for tuberculosis could help fight the novel coronavirus
- by Kelsey Overberg
- Apr 17, 2020
Full story: How a 100-year-old vaccine for tuberculosis could help fight the novel coronavirus
Novant Health Initiates Phase 2 COVID-19 Trial with CytoDyn’s Leronlimab
- by Kelsey Overberg
- Apr 13, 2020
Full story: Novant Health Initiates Phase 2 COVID-19 Trial with CytoDyn’s Leronlimab
INOVIO Initiates Phase 1 Clinical Trial Of Its COVID-19 Vaccine and Plans First Dose Today
- by Kelsey Overberg
- Apr 13, 2020
Full story: INOVIO Initiates Phase 1 Clinical Trial Of Its COVID-19 Vaccine and Plans First Dose Today
Capricor Initiates Compassionate Use Program for Severe COVID-19 Patients using CAP-1002, its Novel Cell Therapy
- by Kelsey Overberg
- Apr 13, 2020
Full story: Capricor Initiates Compassionate Use Program for Severe COVID-19 Patients using CAP-1002, its Novel Cell Therapy
Gilead Sciences Initiates Two Phase 3 Studies of Investigational Antiviral Remdesivir for the Treatment of COVID-19
- by Kelsey Overberg
- Mar 31, 2020
Full story: Gilead Sciences Initiates Two Phase 3 Studies of Investigational Antiviral Remdesivir for the Treatment of COVID-19
Investigational COVID-19 Convalescent Plasma - Emergency INDs
- by Kelsey Overberg
- Mar 31, 2020
Full story: Investigational COVID-19 Convalescent Plasma - Emergency INDs
FDA grants IND “Study May Proceed” for COVID-19 trial to NeuroRx, Inc. in partnership with RELIEF THERAPEUTICS (SIX:RLF) for treatment of Acute Respiratory Distress
- by Kelsey Overberg
- Mar 31, 2020
Full story: FDA grants IND “Study May Proceed” for COVID-19 trial to NeuroRx, Inc. in partnership with RELIEF THERAPEUTICS (SIX:RLF) for treatment of Acute Respiratory Distress
Genentech Announces FDA Approval of Clinical Trial for Actemra to Treat Hospitalized Patients With Severe COVID-19 Pneumonia
- by Kelsey Overberg
- Mar 30, 2020
Full story: Genentech Announces FDA Approval of Clinical Trial for Actemra to Treat Hospitalized Patients With Severe COVID-19 Pneumonia
Pliant Therapeutics raises $100 million in Series C financing to advance therapies for fibrotic diseases
- by Kelsey Overberg
- Mar 20, 2020
Full story: Pliant Therapeutics raises $100 million in Series C financing to advance therapies for fibrotic diseases
FDA Grants Bellerophon Emergency Expanded Access for INOpulse® for the Treatment of COVID-19 Virus
- by Kelsey Overberg
- Mar 20, 2020
Full story: FDA Grants Bellerophon Emergency Expanded Access for INOpulse® for the Treatment of COVID-19 Virus
Bellerophon Announces Agreement with the FDA on its Planned Pivotal Phase 3 Study for the Treatment of Pulmonary Hypertension Associated with Pulmonary Fibrosis
- by Kelsey Overberg
- Mar 20, 2020
Full story: Bellerophon Announces Agreement with the FDA on its Planned Pivotal Phase 3 Study for the Treatment of Pulmonary Hypertension Associated with Pulmonary Fibrosis
FDA Approves First Treatment for Group of Progressive Interstitial Lung Diseases
- by Kelsey Overberg
- Mar 18, 2020
Full story: FDA Approves First Treatment for Group of Progressive Interstitial Lung Diseases
United Therapeutics Announces INCREASE Study Of Tyvaso® Meets Primary And All Secondary Endpoints
- by Kelsey Overberg
- Feb 26, 2020
Full story: United Therapeutics Announces INCREASE Study Of Tyvaso® Meets Primary And All Secondary Endpoints
MediciNova Receives Notice of Intention to Grant for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in Europe
- by Kelsey Overberg
- Feb 4, 2020
Full story: MediciNova Receives Notice of Intention to Grant for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in Europe
aTyr Pharma Announces Positive Interim Safety Results from Ongoing Phase 1b/2a Clinical Trial of ATYR1923
- by Kelsey Overberg
- Dec 18, 2019
Full story: aTyr Pharma Announces Positive Interim Safety Results from Ongoing Phase 1b/2a Clinical Trial of ATYR1923
Bellerophon Announces Positive Top-line Results from Cohort 2 of Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
- by Kelsey Overberg
- Dec 17, 2019
Full story: Bellerophon Announces Positive Top-line Results from Cohort 2 of Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
Indalo Therapeutics presents Phase 1 Clinical Trial results for lead antifibrotic drug candidate IDL-2965
- by Kelsey Overberg
- Dec 4, 2019
Full story: Indalo Therapeutics presents Phase 1 Clinical Trial results for lead antifibrotic drug candidate IDL-2965

Book a PFF Ambassador for your event. Call 844.TalkPFF >

Life with PF

Our Role

Get Involved

Ways to Give

Medical Community

Sponsors and Exhibitors

The Pulmonary Fibrosis Foundation rates among top charities in the U.S. The PFF has a three-star rating from Charity Navigator and is a Better Business Bureau accredited charity. The Foundation has met all of the requirements of the National Health Council Standards of Excellence Certification Program®.

PRIVACY POLICY TERMS OF USE

© 2019 Pulmonary Fibrosis Foundation | 230 East Ohio Street, Suite 500, Chicago, Illinois 60611

p. 888.733.6741 | f. 866.587.9158 | info@pulmonaryfibrosis.org

Join Our Monthly eNewsletter

PRIVACY POLICY TERMS OF USE

© 2019 Pulmonary Fibrosis Foundation | 230 East Ohio Street, Suite 500, Chicago, Illinois 60611

p. 888.733.6741 | f. 866.587.9158 | info@pulmonaryfibrosis.org

Join Our Monthly eNewsletter
Subscribe to receive the most current news and updates from the Pulmonary Fibrosis Foundation.